Dana-Farber Cancer Institute Breast Oncology Center

09/09/2026

Maintaining bone health is an important part of care while taking endocrine therapy.

In this carousel, Caroline Dudman, NP, Senior Nurse Practitioner for the Ductal Carcinoma In Situ (DCIS) Program , shares strategies to support bone health, including exercise, nutrition, and discussing supplements with your care team.

Talk with your healthcare team about the best approach for supporting your bone health during endocrine therapy.

09/08/2026

Did you know that nutrition can play an important role in supporting your overall health while taking endocrine therapy?

In this carousel, Caroline Dudman, NP, Senior Nurse Practitioner for the Ductal Carcinoma In Situ (DCIS) Program , shares nutrition tips to support your health and discusses key nutrients to consider as part of a balanced diet.

Everyone’s nutritional needs are different. Talk with your healthcare team before making significant changes to your diet or starting any new supplements.

09/07/2026

Leg cramps can be a challenging side effect of tamoxifen, especially when they affect sleep or daily activities.

In this carousel, Caroline Dudman, NP, Senior Nurse Practitioner for the Ductal Carcinoma In Situ (DCIS) Program , shares tips that may help manage leg cramps while taking tamoxifen.

If you are experiencing leg cramps, talk with your care team about strategies that may be right for you.

09/04/2026

Join breast oncologist Kristina Fanucci, MD, MHS, for an insightful session on invasive lobular carcinoma (ILC) breast cancer.

Thursday, September 17 at Noon

This session will provide an overview of ILC breast cancer, focusing on its characteristics and current advances in research that are leading to treatments designed specifically for patients with ILC breast cancer.

For more information and to register, visit https://bit.ly/4y6mbb5.

09/04/2026

Join us in-person for a day of support, education, and community designed specifically for affected by .

Whether you are in active treatment, living with metastatic breast cancer, or in long-term survivorship, attend a dedicated event just for you – to hear from the experts and connect with others who “get it.”

🗓️ Friday, October 30 | 8:30 a.m. – 5:30 p.m.
📍 InterContinental Boston Hotel, 510 Atlantic Ave. Boston, MA 02210

Register today ⬇️
https://youngandstrong.dana-farber.org/2026-forum/

09/03/2026

Want to take a deeper dive into the results of the ASCENT-04 and ASCENT-03 trials and what they could mean for people living with metastatic triple-negative breast cancer?

Check out the latest episode of Patient from Hell, where host Samira Daswani speaks with Dr. Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber, about the ASCENT-04 and ASCENT-03 trials, the latest advances in treatment, and how these findings may shape care for people with metastatic triple-negative breast cancer (mTNBC).

In addition to unpacking the new research findings, they discuss:
▪︎ What PD-L1 status means for treatment
▪︎ What are antibody-drug conjugates (ADCs) and how they work
▪︎ Why TROP-2 is an important target in TNBC
▪︎ How immunotherapy works
▪︎ Why tumor sequencing matters, including somatic BRCA, TMB, and clinical trial eligibility
▪︎ How clinical trial findings make their way into the oncologist’s office
▪︎ How TNBC treatment has changed over the past 20 years
▪︎ Advice for someone newly diagnosed with metastatic TNBC

*Note: This podcast was recorded before the FDA approval based on these trial results. On June 24, 2026, the FDA approved sacituzumab govitecan (Trodelvy) as a first-line treatment for metastatic triple-negative breast cancer, either alone or with pembrolizumab depending on PD-L1 status.

🎧 Listen to the full episode: https://youtu.be/GC1Kpf3vKns?si=VPSQxntsqTkh1Ykp

09/02/2026

The U.S. Food and Drug Administration (FDA) has approved the antibody-drug conjugate sacituzumab govitecan (Trodelvy®) for first-line treatment of metastatic triple-negative . The approval is based on results from the ASCENT-03 & -04 global clinical trials, which Sara Tolaney, MD, MPH, chief of the Division of Breast Oncology at -Farber, helped to lead.

Swipe through to learn more about the clinical trial findings and what this new treatment option may mean for patients with metastatic triple-negative breast cancer.

09/01/2026

Join us Sept. 22 in Boston for the OncLive State of the Science Summit on .

This free, in-person meeting is designed for academic & community-based physicians and health care professionals and will cover:
• CDK4/6-based therapies in HR+ breast cancer
• Treatment sequencing in advanced/metastatic HR+/HER2- breast cancer
• Advancements for HER2+ breast cancer
• Updates in triple negative breast cancer
• Plus Live Q&A Sessions

Register today: https://www.onclive.com/events

09/01/2026

Join the EMBRACE Program for a day of wellness, education, and community building! Hosted in collaboration with Dana-Farber’s Zakim Center for Integrative Therapies and Healthy Living, this free event will include tai chi, massage, ear acupuncture, expressive arts, mindful movement, and more.

Open to adults living with and their loved ones.

🗓️ Wednesday, September 9 | 10 a.m. - 3:30 p.m. ET
📍 Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA

Register today ➡️ https://redcapdfci.dfci.harvard.edu/redcap/surveys/?s=9DCNEHYMK37MDCJP

08/31/2026